Loading...
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease
Previous studies identified the Ser/Thr protein kinase, AKT, as a therapeutic target in thrombo-inflammatory diseases. Here we report that specific inhibition of AKT with ARQ 092, an orally-available AKT inhibitor currently in phase Ib clinical trials as an anti-cancer drug, attenuates the adhesive...
Na minha lista:
| Udgivet i: | Haematologica |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Ferrata Storti Foundation
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5286933/ https://ncbi.nlm.nih.gov/pubmed/27758820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.151159 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|